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Since Parodi et al1 reported their initial experience with
endograft placement in patients with abdominal aortic an-
eurysm (AAA) more than a decade ago, endovascular repair
has become an increasingly accepted treatment option for
aneurysmal disease. Currently three endovascular grafts
have been approved by the US Food and Drug Adminis-
tration (FDA), namely, AneuRx, Ancure, and Excluder,
and a number of other devices are at various stages of FDA
review. Endovascular repair of infrarenal AAA has been
extensively investigated, with encouraging short-term re-
sults.2-4 There is little doubt that endovascular repair of
AAA is equivalent to open repair in the short term.5-7 The
enthusiasm for this minimally invasive treatment is driven in
part by shorter hospital course, decreased anesthetic risk,
and expedient convalescent period, compared with the
conventional open operation. Along with numerous posi-
tive short-term and mid-term reports of AAA endovascular
repair, a growing number of reports are beginning to reveal
some of the limitations of this evolving technology. Prob-
lems with device integrity, component separation, migra-
tion, infection, iliac limb occlusion, and aneurysm sac ex-
pansion with and without the presence of endoleak have
been described.8
Many of these problems have resulted in device explan-
tation and repair of the aneurysm with an open surgical
approach. Explantation of an endovascular graft is reported
as primary conversion if it is removed at the original endo-
vascular grafting procedure, and as secondary conversion if
it is removed sometime after the original endovascular
grafting procedure.9 Clearly the rate of primary conversion
has been significantly reduced with improved device de-
sign, patient selection, and increasing operator experi-
ence.10,11 Recently several investigators reported their rate
of secondary conversion. Lyden et al12 evaluated 110 pa-
tients who received endovascular AAA treatment, 5 (4.5%)
of whom required secondary conversion. Dattilo et al13
reported a secondary conversion rate of 2.2% (8 patients)
over 7 years in 362 AAA endovascular grafts. Finally, Ohki
et al,14 in a 9-year experience with 239 endovascular grafts,
reported a secondary conversion rate of 2.1% (5 patients).
In this article we review our experience in patients with late
endovascular graft clinical failure in whom secondary con-
version was required. In addition, we examine the indica-
tions, operative strategies, and technical maneuvers that
may facilitate endograft explantation.
PATIENTS AND METHODS
Medical records for all patients who underwent endo-
vascular AAA repair at Emory University Medical Center
from April 1994 to September 2002 were retrospectively
reviewed after appropriate human ethics committee ap-
proval. We analyzed hospital records, clinic visit reports,
radiographic images, and operative reports for those pa-
tients with delayed clinical failure requiring secondary con-
version. Delayed clinical failure was defined as either graft
infection, loss of device integrity, device thrombosis, or
aneurysm sac expansion with or without endoleak. Three
hundred nineteen patients underwent infrarenal AAA en-
dovascular repair during the study. Types of endografts
implanted are described in Table I. The Ancure and Endo-
vascular Technologies (EVT) tube devices (Guidant, Indi-
anapolis, Ind) and the Excluder device (W. L. Gore &
Associates, Flagstaff, Ariz) were part of investigator-spon-
sored trials. The Talent endograft (Medtronic/AVE, Santa
Rosa, Calif) was used on a compassionate basis, and ap-
proved by our institutional review board committee.
All endovascular AAA procedures were performed in
the operating room, with use of the OEC 9800 or 9600
(OEC Medical Systems, Thousand Oaks, Calif) for fluoro-
scopic guidance. Most patients were given general anes-
thetic, and some were given epidural anesthetic. Surgical
access was through the common femoral artery. All patients
underwent systemic anticoagulation with 100 U/kg of
heparin after femoral access was obtained. Completion
aortography was performed in all patients to assess en-
dograft position, aneurysm exclusion, iliac vessel patency,
and presence of endoleak. Type I endoleak was treated
during the operation with additional endovascular mea-
sures. If a delayed type I leak was discovered during follow-
up, an attempt was made to treat with a percutaneous
endovascular procedure, if possible. Type II endoleak was
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not repaired during the initial operation, but was observed
and monitored with serial imaging for as long as 6 months.
If it did not seal spontaneously, percutaneous embolization
of collateral vessels was attempted. Endografts were ex-
planted (secondary conversion) because of aneurysm sac
enlargement and failed percutaneous therapy for endoleak,
absence of endoleak but increasing aneurysm sac diameter
(endotension), or graft infection.
We followed the anatomic guidelines established for
the current FDA-approved devices in the selection of pa-
tients for AAA endograft placement. In some patients we
used AneuRx aortic cuffs to seal the distal attachment zone
or landed the endograft in the external iliac artery after coil
embolization of the ipsilateral internal iliac artery. Patients
were followed up at 1, 6, and 12 months and annually
thereafter, with contrast medium–enhanced computed to-
mography (CT) and plain radiography. Some patients also
underwent abdominal duplex ultrasound scanning during
the same follow-up intervals. A vascular surgery staff mem-
ber reviewed all radiologic studies.
RESULTS
In 20 patients (6.3%), endografts were deployed but
subsequently were removed and a midline transperitoneal
repair was performed. Nine patients (2.8%) underwent
secondary conversion, and 11 patients (3.4%) underwent
primary conversion to open surgical repair after endovascu-
lar repair. Time from the original endograft procedure to
secondary conversion was 24  13 months (range, 2-48
months). Two grafts were explanted as an urgent proce-
dure, and seven as elective procedures. There were no
intraoperative deaths, but one perioperative death 21 days
after operation, secondary to bacterial endocarditis and
sepsis. Postoperative complications included repeat intuba-
tion because of pulmonary failure in 1 patient, non–Q wave
myocardial infarction in 1 patient, and urinary tract infec-
tion in 2 patients.
Eight of the 9 patients in whom graft explantation was
necessary were men, with mean age 75  7 years (range,
63-86 years). Indications for secondary conversion, type of
device, presence of initial endoleak, and time to explanta-
tion in these 9 patients are outlined in Table II. None of the
patients in whom secondary conversion was required had
inadequate anatomy that predisposed to clinical endograft
failure. Endografts were explanted because of device infec-
tion (AneuRx, n  1), endotension or aneurysm sac en-
largement without evidence of endoleak (Excluder, n  1;
Ancure, n 1), type I endoleak with aneurysm sac enlarge-
ment (Ancure, n  1; EVT tube, n  3), and type II
endoleak with aneurysm sac enlargement (Ancure, n  2).
No graft thrombosis or aneurysm rupture was identified.
Mean AAA diameter at original device implantation was 5.3
 0.4 cm, and at secondary conversion was 6.1  0.8 cm.
The aneurysm sac enlarged more than 5 mm in all patients
except 1 patient with graft infection. Device-specific rate of
explantation was 0.8% for AneuRx, 3.7% for Excluder, 3.1%
for Ancure, and 10.7% for EVT tube.
Surgical details and complications of the nine second-
ary conversion procedures are outlined in Table III. All
procedures were performed with the patient under general
anesthesia, and a midline transperitoneal approach was used
in all patients. In three of the four patients with suprarenal
control, the left renal vein was ligated and divided to
facilitate suprarenal aortic exposure. No patient had renal
failure or renal insufficiency after device explantation. Re-
moval of Ancure, EVT tube, and Excluder endografts
necessitated suprarenal or supraceliac aortic control to fa-
cilitate circumferential detachment of the proximal en-
dograft hooks and barbs. Infrarenal aortic control was used
in three patients, and the endograft (one EVT tube, two
Ancure devices) was transected below the proximal stent or
hook attachment system. The new aortic bypass graft was
anastomosed end-to-end to the infrarenal aorta and proxi-
mal portion of the endograft device. In the two endografts
with nitinol stents (AneuRx, Excluder) ice-cold saline so-
lution was placed around and within the device to help
contract the nitinol stent scaffold. Suprarenal aortic control
was required in the AneuRx infected endograft to allow
adequate debridement of infected aortic tissue and over-
sewing of the aortic stump. The various reconstructions are
also detailed in Table III. Extra-anatomic bypass (axillob-
ifemoral) was used during explantation of the infected
AneuRx endograft. Follow-up data were completed for all
patients who underwent secondary conversion, with mean
follow-up of 29  28 months (range, 4-72 months). Two
patients died during follow-up, from causes unrelated to
aortic aneurysmal disease. Mean length of hospital stay was
20  21 days (range, 7-70 days), and length of ICU stay
was 7  8 days.
DISCUSSION
Endovascular repair of aneurysms has revolutionized
the treatment of aortic aneurysmal disease. With the recent
release of the Excluder endograft, there are now three
FDA-approved devices and others under FDA review. Clin-
ical investigators have confirmed that, compared with open
surgery, endovascular repair results in quicker patient re-
covery and shorter hospital stay.5,15 Reduced early morbid-
ity and less invasive nature of the procedure clearly have
made endovascular AAA repair an appealing alternative for
treatment of aneurysmal disease. Nonetheless, many bene-
fits of an endovascular approach to treatment of AAA may
Table I. Abdominal aortic aneurysm endografts
implanted
Endograft device
Patients (n  319)
n %
Ancure bifurcated (Guidant) 127 40
EVT tube (Guidant) 28 9
Ancure aortoiliac (Guidant) 16 5
AneuRx (Medtronic/AVE) 118 37
Excluder (Gore) 27 8
Talent (Medtronic/AVE) 3 1
EVT, Endovascular Technologies.
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be offset by primary conversion because of access problems
and device failure, need for secondary interventions be-
cause of device failure and endoleak, and delayed problems
resulting in necessary endograft removal. The primary in-
dications for delayed explantation of aortic endografts are
graft infection, device malfunction, device migration, per-
sistent endoleak with increasing aneurysm sac diameter,
aneurysm rupture, and endotension.
However, durability and long-term effectiveness of en-
dovascular AAA repair remains under close scrutiny. Con-
version-related data, including associated mortality among
clinical series reported between 1997 and 2002, are sum-
marized in Table IV. Mean follow-up in these 11 studies
was 30 months, with mean time to secondary conversion of
20 months. Incidence of secondary conversion ranges be-
tween 0.6% and 4.5% (average, 1.9%). Average periopera-
tive mortality related to secondary conversion is 23%. This
significant mortality rate can be attributed to a number of
factors, including small number of patients with fewer than
10 secondary conversion procedures, multiple reasons for
explantation, and diverse patient risk factors.
In our series, persistent endoleak was the most com-
mon indication for conversion. Four patients had type I
endoleak. Of these, three patients had received an EVT
tube graft, and distal attachment site endoleak developed,
whereas in one patient with an Ancure bifurcated graft,
distal iliac limb type I leak developed. Two patients had
enlarging aneurysms, with type II endoleak that persisted
despite attempts at percutaneous coil embolization. Two
patients exhibited the characteristic features of endoten-
sion, with increasing aneurysm sac diameter without docu-
mented endoleak at ultrasound scanning, CT, or conven-
tional angiography. Therefore, in our experience, endoleak
and endotension were the primary indications for second-
ary conversion in 89% (eight of nine patients).
Management of endoleak is evolving. Many endoleaks
can be managed with percutaneous techniques of coil em-
bolization and placement of additional stent components.
Additional techniques include translumbar access to the
aneurysm sac,16 endoscopic ligation of feeding vessels,17
and transperitoneal aneurysm sacotomy with direct ligation
of feeding vessels.18 The role of endoscopic or transperito-
neal ligation of feeding vessels responsible for type II en-
doleak is a useful technique. Percutaneous coil emboliza-
tion of the feeding vessels was attempted in both patients
with type II endoleak in our series. In both patients type II
Table II. Details and indications for secondary conversion
Patient
Device
type
Initial
endoleak*
Months
implanted Indication for conversion
1 EVT
tube
No 30 Endoleak type I, distal attachment
2 EVT
tube
No 32 Endoleak type I, distal attachment; back pain
3 EVT
tube
No 48 Endoleak type I, distal attachment
4 Ancure Type II 12 Endoleak type II, prior coil embolization
5 Ancure Type II 15 Endoleak type I, proximal attachment; acute back pain
6 Ancure No 27 Endotension; successful coil embolization; type II endoleak
7 Ancure No 23 Endoleak type II, multiple coil embolizations attempted
8 AneuRx No 2 Infection
9 Excluder No 24 Endotension
EVT, Endovascular Technologies.
*Initial endoleak noted on completion angiogram at endograft deployment.
Table III. Surgical details of secondary conversions and postoperative complications
Patient Device type
Clamp
location Bypass Intraoperative findings
Postoperative
complications
1 EVT tube Supraceliac Aortobiiliac Distal attachment hook fracture None
2 EVT tube Suprarenal Aortobiiliac Distal attachment hook fracture None
3 EVT tube Infrarenal Aortobiiliac* Distal attachment leak None
4 Ancure Infrarenal Aortobiiliac* Patent lumbar vessel None
5 Ancure Suprarenal Aortobiiliac Proximal and distal attachment leaks Pulmonary failure
6 Ancure Supraceliac Aortobiiliac Patent lumbar vessel UTI, non-Q MI
7 Ancure Infrarenal Aortouniiliac* Patent lumbar vessel and IMA None
8 AneuRx Suprarenal Axillobifemoral Nonincorporated device UTI
9 Excluder Suprarenal Aortobiiliac No endoleak found Endocarditis, death
UTI, Urinary tract infection; MI, myocardial infarction; IMA, inferior mesenteric artery.
*Endograft transected below proximal stent/hook system, and new aortic prosthetic bypass graft was anastomosed end-to-end to infrarenal aorta and proximal
portion of endograft device.
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endoleak persisted; neither patient wanted further interven-
tion, and both chose endograft removal.
There are few series reported in the US literature on
delayed explantation of endografts. Lyden et al12 recently
reviewed their experience with delayed endograft explana-
tion, including removal of one Talent and four Vanguard
endografts. One conversion was necessitated by rupture,
three because of endoleak, and one because of device
malfunction. These authors recommend control of the
aorta well above the proximal fixation site, particularly with
endografts that have barb fixation and suprarenal stenting.
This echoes our experience that awareness of device-spe-
cific characteristics is critical for safe operative removal.
Jacobowitz et al19 reviewed the worldwide experience with
the endovascular grafting system developed by EVT and
reported a 4% secondary conversion rate. Of 669 patients,
27 underwent secondary conversion. Seven percent of pa-
tients (21 of 300) received tube grafts, and 2% (6 of 369)
received Ancure bifurcated devices. Persistent endoleak
with progressive aneurysm sac enlargement was the most
frequent indication for secondary conversion and a statisti-
cally significant increase in delayed conversion observed in
those patients with tube grafts. In this review, a transperi-
toneal approach was used in 93% of cases, and an infrarenal
aortic clamp was applied in nearly half of all patients. In
three patients a significant external fibrotic reaction at the
endograft proximal attachment site was noted. An infrare-
nal aortic clamp was placed across the proximal portion of
the graft, and the endograft was transected below the
proximal stent. The new aortic bypass was constructed with
an end-to-end anastomosis to the proximal endograft and
surrounding infrarenal aortic tissue, as described by
Lawrence-Brown et al.20 However, the authors empha-
sized that inclusion of the transected endograft in the
proximal anastomosis may increase the risk for subsequent
pseudoaneurysm formation, and they recommended an-
nual CT surveillance.
This retrospective review comprises our experience
with four devices, namely, AneuRx, Excluder, Ancure, and
EVT tube grafts, none of which use suprarenal fixation.
Device-specific explantation rates for AneuRx, Excluder,
Ancure, and EVT tube grafts were 0.8%, 3.7%, 3.1%, and
10.7%, respectively. All operations were performed with a
transperitoneal approach. Supraceliac aortic control was
required in two patients, and suprarenal aortic control in
four patients. Overall, we used a clamp above the renal
arteries in two thirds of our patients. Our approach was to
have suprarenal control to enable complete removal of the
endograft, and in many of these patients, once the proximal
portion of the endograft was removed an infrarenal clamp
was placed. Placement of a clamp above the renal arteries
provides more control of the infrarenal aortic neck and
enables removal of the device safely with minimal damage
to the aorta. In three of four patients in whom suprarenal
control was obtained, the left renal vein was transected and
ligated near its origin. Placement of ice cold saline solution
around and within the graft, once aortic inflow was inter-
rupted, was also a helpful adjunct with nitinol-based de-
vices, reducing outward radial forces and thereby facilitat-
ing extraction. Aortobiiliac reconstruction was the
preferred method of repair after explantation.
It bears emphasis that devices with barbs or hooks may
be more difficult to remove with downward traction alone.
Indeed, in three patients (two with Ancure devices and one
with an EVT tube) the new aortic prosthetic graft was
anastomosed directly to the proximal segment of the en-
dograft and the surrounding tissue. Two patients had type
II endoleak, and one had distal attachment type I endoleak.
Thus, in the absence of proximal type I endoleak or graft
infection, it was deemed safe to retain the proximal portion
of the device. An infrarenal aortic clamp was used in all
three patients in whom a portion of the proximal endograft
was incorporated into the proximal anastomosis. We be-
lieve this reduces potential damage to the infrarenal aorta
and eliminates the need to obtain suprarenal aortic control.
With this technique of incorporating the proximal portion
of the endograft into the anastomosis, yearly CT is recom-
Table IV. Reported results of conversion and mortality after endovascular repair
Author Year
Mean
follow-up
Primary conversion
Secondary
conversion
Mortality with
secondary
conversion
Time to
explanation% n % n % n
May et al.,21 1997 11.5 13/113 4.4 5/113 20 1/5
Jacobowitz et al19 1999 40 3 19/669 4 27/669 7 2/27
Cuypers et al22 2000 6 2 38/1871 0.6 11/1871 27 3/11 8
Harris et al23 2000 12 1.3 34/2464 2.1 53/2464 32 17/53 18
Zarins et al24 2001 73 1.3 15/1192 1.5 18/1192 22
Greenberg et al4 2001 14 0.6 3/528 0 0/3 13
Ohki et al14 2001 75 0.8 2/239 2.1 5/239 40 2/5 30
Dattilo et al13 2002 18 1.4 5/362 2.2 8/362 22
Lyden et al12 2002 21 2.7 3/110 4.5 5/110 20 1/5 33
Bockler et al10 2002 23 3.2 17/520 3.8 20/520 12
Chaikof et al25 2002 17 3.8 9/236 1.3 3/236 0 0/3 19
Average  SD 30  25 2.0 155/7776 1.9 158/8304 23 26/112 20  8
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mended to confirm that there is no aneurysm formation at
the proximal anastomosis.
CONCLUSION
Despite the overall high technical and clinical success
rate of endovascular AAA repair, late failure remains a
persistent problem long after initial implantation. Unique
challenges are associated with removal of aortic endografts,
and preoperative planning requires careful consideration of
distinct differences between endograft designs. It is critical
to note that secondary conversion is a more difficult oper-
ation than primary open AAA repair. However, in most
patients explantation can be safely performed with low
morbidity.
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DISCUSSION
Dr Spence M. Taylor (Greenville, SC). Dr Brothers, Secre-
tary Hansen. You have just heard Dr Terramani and his associates
from Emory describe their approach to a new iatrogenic disease
that has developed over the past 10 years, namely, the treatment of
secondary failures of endovascular abdominal aortic aneurysms. In
this presentation they have described the findings and operative
techniques in managing nine patients who required secondary
conversion from endograft to open aneurysm. The paper focuses
nicely on the operative findings and on the methods the authors
used to deal with the unique circumstances that arise intraopera-
tively when treating this new “disease.” This is a small series, and
arguably could be considered a large case report. However, the
smaller size works to the advantage of the authors, allowing them
to detail specifics of management based on the findings of each
case. The authors successfully manage eight cases, with one patient
dying at postoperative day 21, for a perioperative mortality of 11%.
This manuscript, in my judgment, deserves publication because it
is very well-written, it is informative, and adds experience to the
growing collective series of endovascular repairs that need second-
ary conversion. Assuming the authors’ literature research, which
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